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ABSTRACT 
The global crisis of the present era, the COVID-19 pandemic, has changed given new normal ways in many of the sectors. The present review 
highlights the impact, problems, and challenges faced by major areas of the health care sector due to pandemics and also addresses some of the 
aspects of upcoming approaches. The healthcare sector is the one sector that is on-demand since this COVID-19 pandemic raised. During the 
initial period, there was disruption of various services provided by the health care sector due to supply chain management issues and reduction 
in demand by consumers, quarantine, and lockdown period. The healthcare workers also confronted a huge challenge due to the increased 
number of cases and shortage of amenities and safety measures. This significantly affected even COVID-19 patients and the general public 
suffering from other diseases. To fight this issue, research and development (RandD) in pharmaceutical industries with great efforts to explore 
molecules and save many lives. Gradually innovative ways to strengthen and combat pandemics started emerging. Numeral ways and rules 
were adopted to prevent, diagnose and cure the disease. Artificial intelligence technology has emerged as one of the boons to address many of 
the unresolved or time-consuming mysteries. All the divisions of health care sectors have started working more efficiently with adopted new 
strategies to face future challenges.  
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INTRODUCTION  
The pandemic of SARS-Cov, which took birth in China, has turned to 
grapple of historic proportions. As quoted by George Bernard Shaw 
“History repeats itself” [1], and each crisis leaves behind permanent 
structural changes [2], but the man seems to be incapable to learn 
from history. 
On December 31st, 2019, the World Health Organization (WHO) has 
informed the cases of pneumonia of unknown causes in Wuhan City, 
China [3]. The batch of people first infected had shared their 
exposure in the Huanan seafood wholesale market, where not only 
farm animals and seafood but also small carnivore animals like bats 
and snakes were also sold [4]. By 7th January 2020, Betacoronavirus 
which was previously unknown, was reported as a causative agent 
for this novel [5] infection by the Chinese authorities, and it was 
named as “SARS-CoV-2” by the International Committee of 
Taxonomy of Viruses [6] isolated from Human airway epithelial cells 
[7]. Patients infected were observed with common symptoms like 
fever, cough, headache, throat pain, tastelessness, fatigue followed 
by difficulty in breathing. Some patients were also found to have 
sepsis, septic shock, pulmonary edema, severe pneumonia, and acute 
respiratory distress syndrome [8]. This deadly virus infects the 
respiratory, gastrointestinal, hepatic, and central nervous system 
tracts of humans as well as cattle, birds, bats [6], and other wild 
animals. This novel virus possesses a ball-like structure and along 
with some other cell surface proteins. It also possesses a spike-like 
structure on the surface which is made up of glycoprotein gives 
coronaviruses their name [9]. It is the crown-like structure that 
binds to host cells. The researchers found that SARS-CoV-2 
glycoproteins which are like spikes bind to receptors on the human 
cell surface called Angiotensin-converting enzyme 2 (ACE2) and its 
binding capacity was found to be 10 to 20 times more likely than the 
SARS virus of 2002 [10]. Though there are few structural and 
sequence similarities between the SARS 2002 and SARS-CoV-2 the 
unique difference of SARS-CoV-2 is that it cannot bind against three 
different antibodies [11], enabling the interhuman transmission, 
implementing high impact in public health [6]. 
Reverse transcription-polymerase chain reaction (RT-PCR) is the 
confirmatory and final test for individuals for diagnosis and 
confirmation of COVID-19. This test is done by taking swabs from 
the nasal and oral tracts of the suspects, and extracting the viral RNA 
in a printer-like machine, and amplifying it to detect SARS-CoV-2. 
The rapid antibody test is one more test to detect COVID-19 positive 
patients that checks the level of antibodies developed against a 
certain infection. ELISA is another antibody test approved for 
serological surveys to detect the infection in the containment zones 
or population exposed to COVID-19 patients. The drawback of the 
above two tests is they may detect antibodies produced against 
some other infection and show that the sample is positive for 
COVID-19 [12]. Although the deadly virus was isolated from a throat 
swab, consequently, specimens of blood and stool [13] could also 
use to detect it. But document on virus shedding patterns was not 
understood [6], which would help to collect the optimum specimen. 
In contrast to SARS-CoV or Middle East respiratory syndrome MERS-
CoV, this novel SARS-nCoV-2 grows better in primary human airway 
epithelial cells than in vitro standard tissue-culture cells techniques. 
By early March 2020, the World Health Organization claimed COVID-
19 infection to be “PANDEMIC”. By then, it was spread over 200 
countries and territories across the globe. In the first week of June, 
more than 1.4 billion confirmed cases were detected worldwide. As 
of 1:00 pm on 4thAugust 2020 number of confirmed virus cases in 
India is 1,858,689 with a death rate of 39,002 [14]. In this current 
emergent situation when drugs or vaccines are still under clinical 
trials, experts in India have begun with treatment as per the 
guidelines given by the Ministry of Health and Family Welfare 
Directorate General of Health Services. As per the above-stated 
protocol patients with mild complication/condition are 
administered antipyretic, and are also advised to take adequate 
nutrition and hydration. Hydroxychloroquine tablet an old 
antimalarial drug also administered to patients with moderate 
symptoms, those having high-risk features for severe disease [15]. 
Hydroxychloroquine is proved to be safer than chloroquine with 
fewer drug-drug interactions [16, 17]. On May 1, 2020 drug 
Remdesivir gained emergency use authorization (EUA), from FDA 
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[18] and was repurposed to treat severe, hospitalized COVID-19 
patients with oxygen supplementation therapy [19]. Another 
treatment that proved effective is to choose individuals from the 
previous pandemic with a significant reduction in the relative risk of 
mortality, and get convalescent plasma or antibody and use against 
severe acute respiratory infections [20]. Most importantly, the 
current guidelines in The Lancet emphasize that systematic 
corticosteroids should not be given routinely for the treatment of 
COVID-19 [21] that can result in delayed clearance of viral RNA (from 
the previous report of SARS-CoV and MERS-CoV) and other 
complications such as psychosis [22]. Even though there is no specific 
drug/vaccine developed for fighting against COVID-19, preparing a 
route map of people who have come across the COVID-19 patients, 
collection of their appropriate specimen for testing is a priority for 
clinical management and outbreak control [6]. Apart from this, 
restricting the movement of COVID-19 patients either by admitting 
them in the hospitals or by properly making the arrangements for 
their quarantine and treating them until they get back to normal 
health is one more important aspect. This discusses the issues about 
the healthcare sector and assumes that artificial intelligence and 
telehealth play a key role in future perspectives. The review article 
was compiled utilizing search engines include Pubmed, Scopus, 
Science Direct, Google scholar, etc. The articles related to the review 
were compiled from the last 10 y from 2010 to 2020. 
COVID-19 impact on hospital and medical services 
India is one of the worst-hit countries [23] with shooting up 
coronavirus pandemic cases day by day. This pandemic is pushing 
the limits of the healthcare systems [24] and hospital administrators 
are forced to start preparing for worst-case scenarios now [25]. The 
novel COVID-19 pandemic has multiply affected the health care 
sector. In the initial response, there was a serious shortage of 
healthcare facilities, equipment, pharmaceuticals, and skilled 
personnel [26] in hospitals but in contrast, demand for medical 
masks, hand sanitizers, and gloves has significantly increased [27]. 
Loss of life because of an inadequate inventory of drugs or 
ventilators would be tragic [27]. Suspension of most surgical 
procedures focus on reducing excess inpatient capacity, 
postponement of non-COVID-19 health-related issues is walking a 
precarious line [28], OPD (outpatient department) counters 
remained closed for too long, which sparked fears of an impending 
economic crisis and recession in hospital [27]. Cancer patients who 
are already immunocompromised facing a high risk because of the 
need for chemotherapy, they weigh the risks of delaying treatment 
[29]. But when compared with patients suffering from other types of 
cancer, lung cancer patients did not have a higher probability of 
severe complications [30]. Hospitals have a responsibility to 
minimize foreseeable risks to their patients in consideration to that, 
both doctors and nurses are in a dilemma in making decisions on 
patients suffering from paranoid delusions [31, 32].  
Challenges and problems faced by healthcare workers 
Health workers (HWs) are at the forefront of the COVID-19 outbreak 
response and responsible for daily patient care and are directly 
exposed to hazards that put them at high risk of infection [33]. This 
new reality in the healthcare sector comes with a lack of adequate 
personnel and resources. Physicians and nurses are asked to work 
for an extended period of a day or two [26]. Patients in ICU need to 
be shifted to other units to cater to the need for increased cases of 
COVID-19. Later on, as the number of cases started increasing the 
Indian Council of Medical Research (ICMR) approved 176 
government and 78 private hospitals [34] to undertake coronavirus 
testing [35]. However, after the introduction of testing kiosks and 
even drive-through testing recently, shortage of testing kits and 
handling gear and high-test cost have been some of the problems 
faced by private hospitals after scaling up of coronavirus testing 
[20]. Healthcare workers approaching the patients are instructed to 
wrap themselves with a PPE (personal protective equipment) kit 
hence the availability of the gowns must be monitored by the store 
and inventory control. It is reported that currently half of the 
healthcare workforce (that includes nurses, lab workers, and 
housekeeping) are self-reporting the fear of work, inadequate 
facilities, and mental depression altogether has forced them to 
resign. In the year 2020 World Health Organization (WHO) 
identified that there is a shortage of 9 million nurses and midwives 
around the world [36]. Fields R the researchers surveyed the 
healthcare workers to know their opinion on hospital management 
whether the management indulges in the betterment of hospital 
running by implementing novel technology and surveys report says 
that healthcare professionals felt they had insufficient access to 
novel technology, inadequate training may leave employees 
frustrated and confused, the lack of time with patients may be 
exacerbated by an overload of administrative tasks or non-clinical 
assignments, too few staff resulting in high work pressure all this 
would result in poor handling of the pandemic situation in some 
hospitals [37]. 
COVID-19 impact on pharmaceutical industries 
This unprecedented time has brought a negative impact on the 
pharmaceutical industry for a short while of time. Wherein some 
pharma industries remained closed for a certain period as workers 
test positive for COVID-19 [38]. But to prevent this last long special 
COVID-19 HR team was appointed in pharma industries to monitor 
the spread of infection among the employees working within the 
plants. This team includes the panel of doctors to provide virtual 
guidance to employees on health issues, conduct a periodic medical 
checkup, including a thermal checkup/scanning at the entry point 
for all employees, and also prepared a protocol for staff working at 
plants [39]. Unfortunately, Indian pharmaceutical industries faced 
other problems too. Some industries in India rely heavily on China 
for API, starting and intermediate materials for the manufacture of 
generic drugs. At this pandemic period, some generic drugs played a 
crucial role to fight against COVID-19. To name few Indian pharma 
industries manufacturing these generic drugs to include IPCA LABS, 
Zydus Cadila, Mangalam drugs and organics, Wallace Pharma. With a 
canceled or reduced frequency of cargo flights and erratic supply 
chain rendering it impossible for these Indian pharma companies to 
purchase the product from China [38]. This resulted in slow 
production, less availability, and higher costs for the drugs like 
vitamins, penicillin, and also the cost of paracetamol hiked up from 
Rs 250-300 kg to 400-450 kg [40]. Indian pharma industries can sell 
drugs in the US market only after undergoing inspection and get 
approval from US FDA. With the ban on international travel, 
inspection becomes out of topic, rendering it impossible for Indian 
drug companies to sell in the US and other overseas markets [38]. 
Challenges and problems faced by pharmaceutical industries  
The challenges faced by the pharma sector are hoped to be 
temporary. In the present critical situation, pharmaceutical 
companies across the globe are striving very hard to fulfill the huge 
demand for much-needed medicines, vaccines, and medical devices. 
In the global healthcare infrastructure, the Indian pharma sector is 
considered as an important component and an instrument in saving 
millions of lives every year, engaging in manufacturing almost 60 
percent of the vaccines used globally and certainly almost 50 
percent of the US’s generic drug requirements. It’s a matter of pride 
[41] that India belongs to the third-largest pharma sector of the 
world [42]. Medicine choice for COVID-19 often works on a trial and 
error basis [43], which is currently under investigation and yet to be 
fully approved by the FDA that includes hydroxychloroquine, 
lopinavir, and ritonavir, tocilizumab, and sarilumab [44]. 
Chloroquine tablets manufactured by Bayers Pharmaceutical are 
considered as a drug for emergency use by the emergency use 
authorization US government for treating COVID-19 patients. Even 
though Bayer’s had a great hit in revenue during the pandemic time, 
the repurposing of Chloroquine made them balance in their 
business. While Bayer’s would sell 3 million of worth drugs to the 
public, Novartis is engaged in giving back the population 130 million 
doses of Hydroxychloroquine tablets to aid the global pandemic 
[45]. This drug is known to have similar benefits as Chloroquine 
with greater tolerability [46]. An unexpected jump in sales was 
observed with Pfizer’s company in manufacturing the Prevnar 13 
vaccine, which could be used in treating pneumonia in the course of 
the COVID-19 pandemic. Pharmaceutical Company AbbVie is 
engaged in a joint venture with health authorities and several 
institutions involved in clinical studies and research of antiviral 
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drugs lopinavir and ritonavir. The company concluded lopinavir and 
ritonavir as investigational drugs for COVID-19 treatment in various 
countries [47]. Bill gates while commenting on the strength of the 
Indian Pharmaceutical industries, highlighted the contribution of 
Bharat Biotech in developing a vaccine that could immunize the 
whole world to fight against pandemics [48]. COVAXIN an 
inactivated vaccine manufactured and marketed by Bharat biotech 
jointly with ICMR-National institute of virology, received DCGI 
approval is now under Phase II clinical trials [49]. Remdesevir 
antiviral drug from Gilead’s Pharmaceuticals showed a promising 
result in animal studies and is considered as top-ranked drug to help 
battle the coronavirus crisis. This marked increase in the financial 
status of the pharmaceutical company has raised the question of 
whether this pandemic outbreak has come in beneficial to them? 
[45]. The above statement can be justified based on the sales lift in 
Novartis pharmaceutical of 400 million and other companies like Eli-
Lilly, Sanofi Pharmaceuticals having a profit of 280 million during 
the COVID time. 
Future prospects  
Protecting patients and health care workers  
Strategic planning in the healthcare sector has been opened. Many 
health care facilities need to improve and upgrade their 
infrastructure that could help in streamlining and make their 
facilities more conducive to the health and safety of patients, staff, 
and health care professionals. Based on their own experience and 
inputs received from experts, hospital administration would 
emphasize employing effective measures for the future management 
of this kind of pandemic. Eli Perencevich, doctor and epidemiologist 
at the University of IOWA quoted that “Ninety-nine percent of 
alcohol hand rub is placed at the entrance could help in the 
maintenance of hygiene among patients and healthcare workers of 
hospital. There’s some evidence that higher air humidity can reduce 
the viability and airborne transmission of certain kinds of viruses, 
including coronaviruses so hospitals can plan to bump up their 
ventilation rates air in from outside says Kevin Van Den. Handrail in 
hospitals is installed on staircases to serve as support for those 
climbing steps, especially, the sick, the elderly person, visitors, etc. 
But these handrails are silent vehicles for transmitting pathogenic 
bacteria. Transmission of pathogens from toilet lock handles to 
office lock handles was also been identified by Amala, Smart Enoch 
in his studies. Therefore, to prevent these potential pathogens, 
adequate sanitary surveillance should be ensured through the 
provision of soap and water for hand-washing for visitors, 
healthcare workers, and subsequent application of disinfectant 
where necessary [50]. Hospitals in the future must be planned with 
independent rooms for hospitalized patients to reduce hospital-
acquired infections. In 2010, Sweden’s Skane University Hospital an 
infectious-disease building could give an idea for constructing a 
hospital wherein outpatient or suspected Corona patients can give 
entry to several private isolation rooms can bypass the communal 
waiting areas, on the upper floors the inpatient rooms, have doors 
that open onto balconies that wrap around the circular building. 
Patients can be admitted to rooms via the outdoor pathways. The 
doctor from Swedish hospital Torsten Holmdahl, says resolving the 
entrance of COVID patients to the hospital in emergency condition is 
done by giving separate entrances and waiting areas. Scientists have 
also found the virus in stool samples and toilet bowls so flushing an 
uncovered toilet can spray aerosolized droplets of water and waste 
around the room [51]. Toner and Waldhorn suggested his opinion as 
a preventive measure that Physicians, nurses, respiratory therapists, 
pharmacists, environmental services staff, supply chain managers, 
will require a multidisciplinary effort and needed expertise in their 
field [25] to prepare effectively and respond to crises [52]. On expert 
information read from an article published in the American Journal 
of Infection Control, there was a 30 percent reduction of antibiotic 
prescriptions and prescriptions related to common respiratory 
infection in a group that used hand sanitizers [53]. Hospitals and 
healthcare professionals have been recognized as vital not only to 
the safety and well-being of their local communities but also to the 
security and economic health of the nation. To ensure the safety of 
the patients’ outpatient departments (OPD) and in-patients, services 
should be resumed to treat all non-COVID-related cases. To make it 
more convenient, morning and evening shifts in consulting doctors 
can be planned to avoid overcrowding of people or even a prior 
appointment system can also be taken into consideration. 
Healthcare staff involved in treating COVID-19 suspected patients 
should be provided with PPEs, rotation duty, and periodic offs must 
be planned to remove the mental stress felt by the staff. On 
completion of his shift duty, all the staff must be provided with the 
facilities to quarantine in hospital by management to avoid the 
infection to carry over to their families. 
Optimizing telehealth system for recovery from COVID-19 
Almost overnight this pandemic has made healthcare sectors start 
switching towards immediate and universal secure telehealth. It is 
now considered a lifesaving tool that saves time and money. In the 
management of COVID-19 patients, telemedicine has included an 
additional informational page, for guidance about the prevention 
and treatment, training, communication, to assist the remote 
consulting for the community residents and medical staff. This 
enabled to conduct of preliminary screenings through remote 
consultation, which avoided the risk of cross-infection in the 
hospitals. Additionally; helped the medical staff to communicate 
with their colleagues, listen to lectures and apply for consultations 
[54]. This enabled care providers of smaller health care facilities 
situated in the rural areas to connect with specialists in large 
hospitals over a video calling and update them on the latest 
treatment and even demonstration can also be made on certain 
therapeutic aspects, including surgery [55]. With this regard, the 
Indian Space Research Organization (ISRO) began a pilot project 
linking Apollo Hospital in Chennai with Apollo Rural Hospital at 
Aragonda Village in Andhra Pradesh [56]. It not only benefits the 
rural people but people in urban areas, especially [55] at the time of 
a pandemic outbreak, people under quarantine were instructed on 
quarantine processes at home, applications for personal protection, 
and seeking medical attention. Song X with his own experience in 
the telehealth platform suggests that with this innovation, the health 
care sector has got great benefits and also become capable of 
sharing the necessary information and support healthcare 
providers. Telehealth is scaling up in this era, because of achieving 
high-quality outcomes regardless of geography at lower costs, also a 
burden on traveling can be reduced [55]. Centers for Disease Control 
and Prevention (CDC) in 2002, developed Crisis Emergency and Risk 
Communication training module, which is also called a 
communication model “to communicate information that public 
wants or needs to know to reduce the incidence of illness and death” 
in an emergency. Wherein the communication is done by 
“spokesperson” from public health officials or hospital physicians 
from the top official level in front of television [57]. Finally, COVID-
19 lockdown 2.0 in India, long-pending telemedicine guidelines 
were issued by the ministry of health and family welfare (MoHFW), 
in collaboration with NITI Aayog and the Board of Governors (BOG) 
medical Council of India (MCI), these resulted in a surge 
teleconsultations program [58]. 
Application of artificial intelligence in tackling COVID-19  
“Infectious disease surveillance, in particular, the timely detection 
and early warning of disease outbreaks are indeed a function of 
strength and capacity of the health system. The new booming 
artificial Intelligence (AI) has proven as a very good weapon to fight 
back [59] and analyze many issues. In the present situation, Artificial 
Intelligence (AI) has played a major role, starting from the outbreak 
of the virus, virus mutation to its forecast, and is useful in controlling 
this infection in real-time [60, 61]. It has helped the hospitals to 
prepare a strategic plan regarding the requirements. Biosensors 
have helped very efficiently for detecting viral pathogens in the air, 
water, soil surfaces, human and animal tissues and also detect 
symptoms even before people realize they’re infected [62]. In the 
future, this seems to become an important technology to fight 
against other epidemics and pandemics as well [63]. While the 
world waits for a vaccine for COVID-19, Artificial intelligence (AI) 
accelerates the process by reasoning across all available biomedical 
data and information in a systematic search for existing approved 
medicines [64, 65]. White House and a coalition of leading research 
groups in response to the pandemic have started free COVID-19 
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open Research Dataset Challenge(AI’s CORD-19), which contains 
around 200,000 resources and 93,000 full-text articles on SARS-
CoV-2 and related matter [65]. These resources are provided to the 
global research community to apply Artificial intelligence and 
extract relevant medical information from resources and guide the 
practitioners for effective treatment. Artificial intelligence also has a 
promising role starting from the prevention of disease-to predict the 
probable sites of infection, the influx of the virus, the need for beds, 
and necessary information/guidance for healthcare professionals 
during this crisis [60]. BlueDot is a Canadian start-up and Amazon 
web services (AWS) customer that uses AI machine learning 
algorithms to detect disease outbreaks, and first to raise the alarm 
about an outbreak of a respiratory illness in Wuhan, China [6]. 
Insilico methods by using AI have designed six new molecules that 
could limit COVID-19 pneumonia’s ability to virally replicate in cells 
[67]. A neural network is a kind of machine learning method that can 
extract the visual features of this disease and this would help in 
proper monitoring and treatment of the affected individuals [69]. 
Benevolent AI and imperial college London used algorithms to find 
the potential drug targets, which are found to be more promising 
because software pointed to the enzyme adaptor-associated protein 
kinase (AAK1) as possible to target for the disease [67]. For instance, 
experts from the pharmaceutical industries often seek help through 
artificial Intelligence to understand the depth of health crises in 
society.  
CONCLUSION 
Novel COVID-19 pandemic has affected almost all the sectors very 
badly perhaps pharmaceuticals and health care sector are also a 
major hit at the initial lockdown period. Currently, the detection of 
the corona infection is been carried out by taking the swabs from 
nasal and oral tracts of the suspects however, since the presence of 
the virus is also reported from the stool samples of the patients 
hence alternatively examining fecal samples of the suspects for the 
confirmation of the virus can be thought of. The usage of face masks, 
hand gloves, and hand sanitizers has greatly increased by health 
workers and also by the general public. Although there was a 
shortage of ventilators and PPE kits supply initially but gradually, it 
is adequately supplied now. Doctors and nurses and allied health 
workers are forced to work many extra hours to treat the over the 
rush of COVID 19 patients which are causing them stress and 
exposing them to great health risk in this situation some 
governments came forward to announce the life insurance policy to 
corona warriors which are a welcome move, in addition, hospital 
management should also think to compensate the health care 
professionals involved in treating the corona patients with good 
incentives or other benefits. During this COVID 19 pandemic 
telemedicine was experimented very well by most of the doctors to 
reach out to their patients and to provide consultation, so this in 
future can be of major help in case of any such outbreaks. Artificial 
intelligence is much to offer future as in this biosensor were initially 
helped to find the pandemic in future, they can be adopted great way 
to detect the outbreaks. This pandemic also made to think about 
constructing the wards in the hospitals in a special way to offer not 
only a better for the such rapid spreading infected patients but also 
to avoid the other outpatients and other admitted in-patients with 
other complications from such isolation wards. As symptomatic 
treatment was offered for the patients initially such as 
Hydroxychloroquine, Lopinavir, Ritonavir, Tocilizumab, and 
Sarilumab. Thus, pharmaceutical companies were asked to 
manufacture these drugs in bulk quantity to cater to the world's 
needs and in the first quarter of this year, it was seen that there was 
a great surge in the manufacture and distribution of these drugs 
especially hydroxychloroquine by renowned pharmacy companies 
worldwide. India and China played a major role in supplying these 
drugs to many countries around the world. As this pandemic hit the 
world’s economy very badly, after the lockdown of more than two 
months slowly many countries started to unlock the movement of 
transport, public and other processes to normalize and help the 
common public to lead their normal life. As the process of unlocking 
began the number of COVID 19 cases is also increasing drastically as 
sometimes it is hard to follow strictly the guidelines suggested by 
the health authorities. This situation necessitates the strong 
immunization of the people such as vaccines or interferons which 
can effectively save the life of patients against such infections. 
Inactivated COVID 19 vaccines are tried in laboratory animals and 
also in humans on a small scale by some pharmaceutical companies 
but still, it will take time to complete the clinical trials and to get 
final approval by authorities to reach the people, till then it is 
advised to work by maintaining social distancing, protecting oneself 
with mask, by employing hand sanitization and avoid overcrowding. 
Certainly, new potential therapeutic regimens will emerge out with 
the researches going on across the globe with the rapid phase 
against this rapidly spreading COVID 19 virus. Let us be optimistic 
and work safely to save ourselves and serve the community. 
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